AU2007307007A1 - Omega-3 fatty acids and dyslipidemic agent for reduction of apo-B levels - Google Patents
Omega-3 fatty acids and dyslipidemic agent for reduction of apo-B levels Download PDFInfo
- Publication number
- AU2007307007A1 AU2007307007A1 AU2007307007A AU2007307007A AU2007307007A1 AU 2007307007 A1 AU2007307007 A1 AU 2007307007A1 AU 2007307007 A AU2007307007 A AU 2007307007A AU 2007307007 A AU2007307007 A AU 2007307007A AU 2007307007 A1 AU2007307007 A1 AU 2007307007A1
- Authority
- AU
- Australia
- Prior art keywords
- omega
- fatty acids
- levels
- apo
- ldl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
- A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US85028006P | 2006-10-10 | 2006-10-10 | |
| US60/850,280 | 2006-10-10 | ||
| PCT/US2007/021631 WO2008045465A1 (en) | 2006-10-10 | 2007-10-10 | Omega-3 fatty acids and dyslipidemic agent for reduction of apo-b levels |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2007307007A1 true AU2007307007A1 (en) | 2008-04-17 |
Family
ID=39283166
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2007307007A Abandoned AU2007307007A1 (en) | 2006-10-10 | 2007-10-10 | Omega-3 fatty acids and dyslipidemic agent for reduction of apo-B levels |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP2089014A4 (es) |
| JP (1) | JP2010505956A (es) |
| KR (1) | KR20090080070A (es) |
| CN (2) | CN101553221A (es) |
| AU (1) | AU2007307007A1 (es) |
| BR (1) | BRPI0719182A2 (es) |
| CA (1) | CA2672919A1 (es) |
| EA (2) | EA018734B1 (es) |
| MX (1) | MX2009003921A (es) |
| WO (1) | WO2008045465A1 (es) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8784886B2 (en) | 2006-03-09 | 2014-07-22 | GlaxoSmithKline, LLC | Coating capsules with active pharmaceutical ingredients |
| JP2010506920A (ja) * | 2006-10-18 | 2010-03-04 | リライアント・ファーマシューティカルズ・インコーポレイテッド | Ｌｐ−ｐｌａ２濃度を減少させるためのオメガ−３脂肪酸 |
| US20110236476A1 (en) | 2008-09-02 | 2011-09-29 | Amarin Corporation Plc. | Pharmaceutical composition comprising eicosapentaenoic acid and nicotinic acid and methods of using same |
| HUE048299T2 (hu) | 2009-02-10 | 2020-07-28 | Amarin Pharmaceuticals Ie Ltd | Eikozapentaénsav-etil-észter hipertrigliceridémia kezelésére |
| WO2010127103A1 (en) | 2009-04-29 | 2010-11-04 | Amarin Pharma, Inc. | Stable pharmaceutical composition and methods of using same |
| SG175390A1 (en) | 2009-04-29 | 2011-12-29 | Amarin Corp Plc | Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same |
| SI2443246T1 (en) | 2009-06-15 | 2018-05-31 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy |
| SG10201405994UA (en) | 2009-09-23 | 2014-10-30 | Amarin Pharmaceuticals Ie Ltd | Pharmaceutical Composition Comprising Omega-3 Fatty Acid And Hydroxy-derivative Of A Statin And Methods Of Using Same |
| US11712429B2 (en) | 2010-11-29 | 2023-08-01 | Amarin Pharmaceuticals Ireland Limited | Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity |
| EP2646013A4 (en) | 2010-11-29 | 2014-03-26 | Amarin Pharma Inc | Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity |
| WO2013070735A1 (en) | 2011-11-07 | 2013-05-16 | Amarin Pharmaceuticals Ireland Limited | Methods of treating hypertriglyceridemia |
| US11291643B2 (en) | 2011-11-07 | 2022-04-05 | Amarin Pharmaceuticals Ireland Limited | Methods of treating hypertriglyceridemia |
| ES2891473T3 (es) | 2012-01-06 | 2022-01-28 | Amarin Pharmaceuticals Ie Ltd | Composiciones y métodos para reducir los niveles de alta sensibilidad (hs-CRP) en un sujeto |
| WO2014005013A2 (en) | 2012-06-29 | 2014-01-03 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing the risk of a cardiovascular event in a subject on statin therapy |
| CN102824636A (zh) * | 2012-08-15 | 2012-12-19 | 四川大学 | 一种含他汀类药物和多不饱和脂肪酸的药物组合物及其用途 |
| WO2014034871A1 (ja) * | 2012-08-30 | 2014-03-06 | 株式会社 三和化学研究所 | 脂質異常症の予防又は治療薬 |
| WO2014074552A2 (en) | 2012-11-06 | 2014-05-15 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy |
| US20140187633A1 (en) | 2012-12-31 | 2014-07-03 | Amarin Pharmaceuticals Ireland Limited | Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis |
| US9814733B2 (en) | 2012-12-31 | 2017-11-14 | A,arin Pharmaceuticals Ireland Limited | Compositions comprising EPA and obeticholic acid and methods of use thereof |
| US9452151B2 (en) | 2013-02-06 | 2016-09-27 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing apolipoprotein C-III |
| US9624492B2 (en) | 2013-02-13 | 2017-04-18 | Amarin Pharmaceuticals Ireland Limited | Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof |
| US9662307B2 (en) | 2013-02-19 | 2017-05-30 | The Regents Of The University Of Colorado | Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof |
| US9283201B2 (en) | 2013-03-14 | 2016-03-15 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for treating or preventing obesity in a subject in need thereof |
| US20140271841A1 (en) | 2013-03-15 | 2014-09-18 | Amarin Pharmaceuticals Ireland Limited | Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin |
| US10966968B2 (en) | 2013-06-06 | 2021-04-06 | Amarin Pharmaceuticals Ireland Limited | Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof |
| US20150065572A1 (en) | 2013-09-04 | 2015-03-05 | Amarin Pharmaceuticals Ireland Limited | Methods of treating or preventing prostate cancer |
| US9585859B2 (en) | 2013-10-10 | 2017-03-07 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy |
| CA2938718C (en) * | 2014-02-05 | 2022-10-18 | Dezima Pharma B.V. | Cholesteryl ester transfer protein (cetp) inhibitor and pharmaceutical compositions comprising said inhibitor for use in the treatment or prevention of cardiovascular diseases |
| US10561631B2 (en) | 2014-06-11 | 2020-02-18 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing RLP-C |
| US10172818B2 (en) | 2014-06-16 | 2019-01-08 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids |
| US10406130B2 (en) | 2016-03-15 | 2019-09-10 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids |
| TW201900160A (zh) | 2017-05-19 | 2019-01-01 | 愛爾蘭商艾瑪琳製藥愛爾蘭有限公司 | 用於降低腎功能下降之個體中的三酸甘油酯之組合物及方法 |
| US11058661B2 (en) | 2018-03-02 | 2021-07-13 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L |
| HUE067138T2 (hu) | 2018-09-24 | 2024-10-28 | Amarin Pharmaceuticals Ie Ltd | Módszerek kardiovaszkuláris események veszélyének csökkentésére egy alanyban |
| CN116350616A (zh) | 2019-11-12 | 2023-06-30 | 阿马里纳药物爱尔兰有限公司 | 降低心房纤颤和/或心房扑动受试者心血管事件风险的方法 |
| US11986452B2 (en) | 2021-04-21 | 2024-05-21 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing the risk of heart failure |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030170643A1 (en) * | 1999-10-26 | 2003-09-11 | Edward Fisher | Regulation of apoB treatment and drug screening for cardiovascular and metabolic disorders or syndromes |
| JP2008522970A (ja) * | 2004-12-06 | 2008-07-03 | レリアント ファーマスーティカルズ インコーポレイテッド | 脂質療法用のオメガ−３脂肪酸類及び異常脂質血症薬剤 |
| KR20080037674A (ko) * | 2005-07-18 | 2008-04-30 | 릴라이언트 파마슈티컬스 인코퍼레이티드 | 아제티디논계 콜레스테롤 흡수 억제제 및 오메가-3 지방산및 이들의 조합물로의 치료 |
-
2007
- 2007-09-07 CN CNA2007800456489A patent/CN101553221A/zh active Pending
- 2007-09-07 EA EA200970359A patent/EA018734B1/ru not_active IP Right Cessation
- 2007-10-10 CA CA002672919A patent/CA2672919A1/en not_active Abandoned
- 2007-10-10 JP JP2009532391A patent/JP2010505956A/ja active Pending
- 2007-10-10 EP EP07852630A patent/EP2089014A4/en not_active Withdrawn
- 2007-10-10 MX MX2009003921A patent/MX2009003921A/es unknown
- 2007-10-10 EA EA200970360A patent/EA200970360A1/ru unknown
- 2007-10-10 KR KR1020097009523A patent/KR20090080070A/ko not_active Withdrawn
- 2007-10-10 CN CNA2007800456667A patent/CN101553220A/zh active Pending
- 2007-10-10 AU AU2007307007A patent/AU2007307007A1/en not_active Abandoned
- 2007-10-10 BR BRPI0719182-0A2A patent/BRPI0719182A2/pt not_active Application Discontinuation
- 2007-10-10 WO PCT/US2007/021631 patent/WO2008045465A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| EA018734B1 (ru) | 2013-10-30 |
| EA200970360A1 (ru) | 2009-10-30 |
| JP2010505956A (ja) | 2010-02-25 |
| EP2089014A1 (en) | 2009-08-19 |
| CN101553221A (zh) | 2009-10-07 |
| CA2672919A1 (en) | 2008-04-17 |
| BRPI0719182A2 (pt) | 2014-10-21 |
| MX2009003921A (es) | 2009-08-31 |
| EP2089014A4 (en) | 2009-12-09 |
| CN101553220A (zh) | 2009-10-07 |
| KR20090080070A (ko) | 2009-07-23 |
| WO2008045465A1 (en) | 2008-04-17 |
| EA200970359A1 (ru) | 2009-10-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2007307282B2 (en) | Statin and omega-3 fatty acids for reduction of Apo-B levels | |
| AU2007307007A1 (en) | Omega-3 fatty acids and dyslipidemic agent for reduction of apo-B levels | |
| US8871800B2 (en) | Statin and omega-3 fatty acids for reduction of Apo-B levels | |
| CA2589654C (en) | Omega-3 fatty acids and dyslipidemic agent for lipid therapy | |
| US20110092563A1 (en) | Statin and omega-3 fatty acids for lipid therapy | |
| US20110251275A1 (en) | Omega-3 fatty acids for reduction of lp-pla2 levels | |
| US20060211763A1 (en) | Treatment with Statin and Omega-3 Fatty Acids and a Combination Product Thereof | |
| CN101098690A (zh) | 用于血脂治疗的ω-3脂肪酸和脂血异常剂 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK1 | Application lapsed section 142(2)(a) - no request for examination in relevant period |